CD274 and non-small cell lung carcinoma: A multicentre, randomised, open-label, phase 3 trial revealed that the treatment benefit was observed in terms of overall survival and progression-free survival in the subgroup populations when atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy as the first-line treatment for metastatic nonsquamous non-small-cell lung cancer, regardless of PDL1 expression [8].